Gilead Sciences | GILD - SCHULD

Aktienkurs
145.13
Täglich Wechseln
-3.09 -2.08%
Monatlich
-4.83%
Jährlich
25.07%
Q1 Prognose
144.39




SCHULD Veränderung Datum
AbbVie USD 1000K 70.48B 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
ALKERMES USD 71.6M 1.08M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amgen USD 54.59B 1.62B 2025-09
Biogen USD 6.29B 1.7M 2025-12
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.51B 2.6B 2025-09
Gilead Sciences USD 24.94B 5M 2025-09
GlaxoSmithKline GBP 17.75B 396M 2025-09
Glaxosmithkline GBP 17.75B 396M 2025-09
Incyte USD 40.41M 855K 2025-12
J&J USD 45.8B 4.97B 2025-09
Merck USD 41.37B 5.97B 2025-09
Moderna USD 734M 7M 2025-09
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Novartis USD 32.64B 1.37B 2025-06
Pfizer USD 60.85B 78M 2025-09
PTC Therapeutics USD 286.32M 306K 2025-09
Puma Biotechnology USD 89.06M 55.07M 2024-06
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Sangamo BioSciences USD 0 0 2022-06
Sanofi EUR 21.76B 530M 2025-09
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
United Therapeutics USD 200M 100M 2025-03
Vertex Pharmaceuticals USD 1.83B 307.4M 2025-09